NCT03795441View on ClinicalTrials.gov

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

July 28, 2019

Study Completion Date

July 28, 2019

Conditions

Healthy

Interventions

BIOLOGICAL

Ad26.RSV.preF

Ad26.RSV.preF will be administered as intramuscular injection on Day 1.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT03795441 - A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults | Biotech Hunter | Biotech Hunter